



1631

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE **RECEIVED**

MAY 08 2003

Applicant(s): Paul Young
Serial No: 09/954,456 Art Unit: 1631 TECH CENTER 1600/2900
Filed: 18 September 2001 Examiner: C. L. Smith
Title: PROCESS FOR IDENTIFYING ANTI-CANCER THERAPEUTIC AGENTS USING CANCER GENE SETS
Docket No: 669290-76

1 May 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application. In addition, a supplemental disclosure statement has been filed citing related copending applications.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

§1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits.
No fee or statement is required.

§1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR

(2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

The statement as specified in 37 CFR §1.97(e) set out below; OR
 The fee of \$ 180.00 under 37 CFR §1.17(p).

§1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

(1) a Final Action or under 37 CFR §1.113; OR
(2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND

is accompanied by:

(1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
(2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
(3) The petition fee of \$130.00 set out in 37 CFR §1.17(i).

X §1.97(e) The undersigned Attorney hereby states that:

X each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or

no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

Alan J. Grant 5/11/03

Alan J. Grant, Esq. Date

Respectfully submitted,

Alan J. Grant

Alan J. Grant, Esq.
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
Six Becker Farm Road
Roseland, NJ 07068
Phone: 973-994-1700
Fax: 973-994-1744

Form PTO-1449

Atty. Docket:

689290-76

Serial No.

09/954,426

INFORMATION DISCLOSURE STATEMENT

Applicant: Paul Young

Filing Date: 18 September 2001

Group: 1631

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
	A1	5,882,874	March 16, 1999	Fisher			
	B1						
	C1						

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Sub-Class	Translation
	E1	WO 95/19369	20 July 1995	PCT			<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	F1	WO 99/50278	7 Oct. 1999	PCT			<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	V1	Cheng et al., "Characterizations of taxol-induced Apoptosis and Altered Gene Expression in Human Breast Cancer Cells," Cellular Pharmacology, Vol. 2, 249-257 (1995).
	W1	Siavoshian et al., "Subtractive Hybridization and Differential Screening Identified Two Genes Differentially expressed after Induction of <i>in Vitro</i> (Atypical) Terminal Differentiation in the NSCLC-N6 Cell Line by a Marine Substance (Bistramide K), Anticancer Research, Vol. 19, 5361-5366 (1999).
	X1	Kurdistani et al., "Inhibition of Tumor Cell Growth by RTP/rit42 and Its Responsiveness to p53 and DNA Damage", Cancer Research, Vol. 58, pages 4439-4444, October 1, 1998.
	Y1	Hess et al., "Application of Differential cDNA Screening Techniques to the Identification of Unique Gene Expression in Tumours and Lymphocytes" in CURRENT OPINION IN IMMUNOLOGY, Vol. 10, pages 125-130 (1998).
	Z1	Vietor et al., "In Search of Differentially Expressed Genes and Proteins," BBA, Vol. 1359, pages 187-199 (1997).
	AA	Hillier et al, "ze23c03.s1 Soares fetal heart, H. sapiens cDNA clone, m RNA sequence" DATABASE EBI 'Online', EMBL, Database Accession No. AA011199 (3 August 1996).
	BB	
	CC	
	DD	
	EE	

Examiner:

Date Considered:

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.